Penumbra, Inc. (PEN)

NYSE: PEN · IEX Real-Time Price · USD
270.07
+3.90 (1.47%)
Mar 21, 2023, 4:00 PM EDT - Market closed
1.47%
Market Cap 10.31B
Revenue (ttm) 847.13M
Net Income (ttm) -2.00M
Shares Out 38.18M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE 277.78
Dividend n/a
Ex-Dividend Date n/a
Volume 278,274
Open 267.21
Previous Close 266.17
Day's Range 264.77 - 270.70
52-Week Range 114.87 - 274.71
Beta 0.52
Analysts Buy
Price Target 297.23 (+10.06%)
Earnings Date May 2, 2023

About PEN

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Sep 18, 2015
Employees 3,800
Stock Exchange NYSE
Ticker Symbol PEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for PEN stock is "Buy." The 12-month stock price forecast is $297.23, which is an increase of 10.06% from the latest price.

Price Target
$297.23
(10.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Are These Medical Device Makers Getting Ready To Rally?

Large-cap medical device maker Stryker Corp. (NYSE: SYK) is consolidating along its 50-day moving average, a bullish sign as the stock takes a breather after a run-up that began last year.

Other symbols: ALGNLNTHSYK
1 week ago - MarketBeat

Penumbra (PEN) Q4 Earnings Top Estimates, Sales Remain Robust

Penumbra's (PEN) sales during the fourth quarter reflect continued demand for its products. The 2023 outlook is encouraging as EPS improves despite macro challenges.

3 weeks ago - Zacks Investment Research

Penumbra (PEN) Q4 Earnings and Revenues Surpass Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 14.29% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Penumbra, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

ALAMEDA, Calif. , Feb. 23, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and ful...

3 weeks ago - PRNewsWire

Should You Buy Penumbra (PEN) Ahead of Earnings?

Penumbra (PEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

3 weeks ago - Zacks Investment Research

Penumbra, Inc. to Present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference

ALAMEDA, Calif. , Feb. 16, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Co...

1 month ago - PRNewsWire

Penumbra (PEN) Earnings Expected to Grow: Should You Buy?

Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

4 Low-Beta Stocks to Buy to Sail Through the Volatile Market

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Patria Investments (PAX), Lamb Weston (LW) and BJ's Wholesale (BJ) are poised to gain.

Other symbols: BJLWPAX
1 month ago - Zacks Investment Research

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 23, 2023

ALAMEDA, Calif. , Jan. 26, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2022 af...

1 month ago - PRNewsWire

PENUMBRA LAUNCHES LATEST INNOVATION IN MECHANICAL THROMBECTOMY: LIGHTNING FLASH™

Lightning Flash™ is the most advanced mechanical thrombectomy system on the market to address venous and pulmonary thrombus Next generation technology combines superior catheter design with the latest...

2 months ago - PRNewsWire

Penumbra, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference

ALAMEDA, Calif. , Dec. 19, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 41st Annual J.P.

3 months ago - PRNewsWire

Penumbra Launches First Hands-Free, Full Body Virtual Reality-Based Offering for Rehabilitation, Expanding REAL® System Platform

ALAMEDA, Calif.--(BUSINESS WIRE)--Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the first full body, non-tethered immersive healthcare offe...

4 months ago - Business Wire

Penumbra (PEN) Tops Q3 Earnings and Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 200% and 0.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Penumbra, Inc. Reports Third Quarter 2022 Financial Results

ALAMEDA, Calif. , Nov. 3, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended Sep...

4 months ago - PRNewsWire

Penumbra, Inc. to Present at the Jefferies London Healthcare Conference

ALAMEDA, Calif. , Nov. 1, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Jefferies London Healthcare Conference on Tuesday, Nov...

5 months ago - PRNewsWire

Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Penumbra, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 3, 2022

ALAMEDA, Calif. , Oct. 6, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2022 after market close...

5 months ago - PRNewsWire

Penumbra and Asahi Intecc Partner With Goal of Introducing Indigo™ System Including Lightning™ Intelligent Aspiration to Japan

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra and Asahi Intecc Co. will collaborate to introduce Penumbra's Indigo™ Aspiration System into the Japanese market upon regulatory approval.

6 months ago - Business Wire

Penumbra (PEN) Surges 6.2%: Is This an Indication of Further Gains?

Penumbra (PEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

6 months ago - Zacks Investment Research

Penumbra Announces European Launch of RED® Reperfusion Catheters for Stroke Care

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra's RED® Reperfusion Catheters are now commercially available in Europe.

6 months ago - Business Wire

Latest Data Demonstrates Penumbra System and RED® Reperfusion Catheters Effective for Broad Stroke Care

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced initial INSIGHT Registry data showing Penumbra's...

7 months ago - Business Wire

Penumbra, Inc. to Present at Upcoming Investor Conferences

ALAMEDA, Calif. , Aug. 24, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times...

7 months ago - PRNewsWire

Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 114.29% and 1.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Penumbra, Inc. Reports Second Quarter 2022 Financial Results

ALAMEDA, Calif. , Aug. 4, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended Ju...

8 months ago - PRNewsWire

Penumbra, Inc. to Present at the Canaccord Genuity 42nd Annual Growth Conference

ALAMEDA, Calif. , July 27, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 42nd Annual Growth Conference on We...

8 months ago - PRNewsWire